Compare Regeneron Pharmaceuticals Inc (REGN) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Schwab US Dividend Equity ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while Schwab US Dividend Equity ETF trades at $32.91. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Schwab US Dividend Equity ETF pays none, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | SCHD | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $812.27 | $33.04 |
52-Week Low | $545.46 | $26.38 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
SCHD trades at $32.75, down 0.49% today, with technical indicators showing a bullish trend supported by moving averages. The ETF has delivered strong 2026 performance with a 22% year-to-date return and recently surpassed $100 billion in assets under management. Recent news highlights its defensive sector allocation and consistent dividend growth, with a current yield below its historical average due to price appreciation.
The outlook remains positive given SCHD's quality screening methodology and institutional inflows, though risks include interest rate sensitivity and market volatility. Analyst sentiment is bullish with the fund positioned as a defensive income play with capital appreciation potential in uncertain markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
